top of page
Novus Dx Logo on the Microfluidics Innovation Hub website.
Open Call Project
Innovation in Sepsis Diagnostics: Novus Dx's Rapid Detection Technology

Revolutionizing Sepsis Diagnostics with Novus Dx's Rapid Detection Technology

Sepsis, a life-threatening response to infection, demands rapid and precise diagnosis to improve patient outcomes. Novus Diagnostics, in collaboration with the Microfluidics Innovation Hub (MIH), is pioneering a breakthrough in sepsis diagnostics with their advanced technology, SepTec. This innovative platform provides near-patient, rapid detection of sepsis-causing pathogens within 15 minutes, offering a transformative solution to the critical challenges in sepsis management.

The Challenge with Traditional Methods

Traditional methods of diagnosing sepsis, such as blood cultures or PCR, are often slow and complex, typically taking several hours to days. These delays can be fatal, as timely and appropriate treatment is crucial. The need for faster, more efficient diagnostic tools is imperative to reduce sepsis-related mortality and improve patient care.

Novus Dx's Innovative Approach

At the core of Novus Dx's solution is the SepTec assay, an in vitro diagnostic device designed to detect and differentiate sepsis pathogens directly from whole blood. This technology leverages antibody-mediated capture combined with electrochemical impedance spectroscopy (EIS) to identify gram-positive bacteria, gram-negative bacteria, and fungal pathogens quickly and accurately.

Key Components of SepTec:

  • Analyzer Instrument: Automates the diagnostic process and provides results in real-time.

  • Disposable Cartridge: Features a patented nano-textured membrane and specific antibodies to capture and identify pathogens.

  • Microfluidic Technology: Facilitates the movement and processing of blood samples within the cartridge, ensuring efficient and precise detection.

The Impact on Diagnostics and Treatment

Novus Dx's SepTec technology promises to revolutionize sepsis diagnostics by delivering several critical benefits:

  • Speed: Provides results within 15 minutes, enabling immediate clinical decisions and early initiation of targeted antimicrobial therapy.

  • Accuracy: High sensitivity (100%) and specificity (>95%) minimize false positives and negatives, ensuring reliable pathogen detection.

  • Cost-Effectiveness: Simplifies the diagnostic process and reduces costs by eliminating the need for central lab facilities and specialized personnel.

  • Antibiotic Stewardship: Promotes targeted antimicrobial therapy, reducing the use of broad-spectrum antibiotics and helping to combat antibiotic resistance.

Join us in revolutionizing sepsis diagnostics

Join us in revolutionizing sepsis diagnostics with Novus Dx’s SepTec technology! Contact us today to learn how our rapid and accurate diagnostic solution can transform patient care and improve outcomes in sepsis management.

Photo of Novus Dx’s SepTec technology showcasing its components and the process of sepsis pathogen detection.

Develop a rapid diagnostic system for near-patient sepsis detection.
Optimize the technology to provide high sensitivity and specificity in pathogen detection.
Ensure cost-effective and scalable production of the diagnostic cartridges.


Project Management and Communication: MIH oversees all project activities, ensuring timely and effective progress.
Scalable Manufacturing Approaches: INM focuses on the development of scalable micropatterning methods for sensor regions.
Thin Film Deposition and UV-NIL Stamping: JR handles the deposition of gold layers and UV-NIL stamping for electrode formation.
Antibody Functionalization: SCI develops scalable methods for the functionalization of sensor surfaces with target antibodies.
Fluid Dynamics Simulations: BST conducts simulations to optimize the deposition of reagents and enhance microfluidic efficiency.


Rapid detection and differentiation of gram-positive bacteria, gram-negative bacteria, and fungal pathogens.
High sensitivity and specificity to ensure accurate and reliable results.
Cost-effective production of disposable cartridges suitable for point-of-care settings.
User-friendly design that integrates easily into clinical workflows.

The Role of the #MIHfamily

  • Microfluidics Innovation Hub (MIH): Manages and coordinates the project, ensuring efficient development and commercialization.

  • INMOLD (INM): Handles scalable manufacturing and micropatterning of sensor regions.

  • Joanneum Research (JR): Provides expertise in gold layer deposition and UV-NIL stamping for electrode design.

  • SIENION (SC)I: Develops methods for antibody immobilization on sensor surfaces.

  • Bionic Surface Technologies (BST): Offers fluid dynamics simulations to optimize reagent deposition and microfluidic performance.

Partners Involved

Stay Tuned

Stay updated as Novus Dx and MIH continue to innovate in sepsis diagnostics. Discover how our joint efforts are transforming the detection and treatment of this life-threatening condition, paving the way for better patient care and outcomes.

Services and Technologies

Together with the #MIHfamily, Novus Dx is driving a revolution in sepsis diagnostics. The combined expertise and collaborative spirit of MIH and its partners are propelling SepTec towards successful development and market entry, setting new standards in rapid pathogen detection.

This project has received funding from the European Union’s HORIZON 2020 research & innovation programme under grant agreement no. 862092.

bottom of page